Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Anthrax Vaccine Market Evolve in Terms of Growth and Size by 2029?

The size of the anthrax vaccine market has seen consistent growth over the past few years. It is expected to rise from $11.27 billion in 2024 to $11.77 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.4%. The market growth during the historical period can be attributed to factors such as concerns over biological warfare, demand from the military, instances of anthrax outbreaks, readiness in public health, and biodefense initiatives.

In the coming years, the anthrax vaccine market size is projected to experience consistent growth. Its estimated value will reach “$14 billion by 2029 with a compound annual growth rate (CAGR) of 4.4%. This anticipated growth during the forecast period is mainly driven by global security issues, emerging risks, governmental purchases, and readiness for pandemics. Technological progress, increased accessibility in developing countries, emphasis on next-generation vaccines, expanded governmental stockpiling and cooperative research endeavors are set to be the key trends during the forecast period.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

What factors are expected to fuel Anthrax Vaccine market growth in the coming years?

The escalating occurrence of contagious ailments is predicted to boost the anthrax vaccine market’s expansion. Contagious diseases are health conditions triggered by harmful microorganisms, inclusive of bacteria, viruses, parasites, or fungi. These diseases can transmit directly or indirectly between individuals, often leading to symptoms that vary in severity, sometimes leading to death, influenced by the pathogen and the person’s immune reaction. The rising occurrence of infectious diseases stems from demographic shifts worldwide, urbanization, environmental and land use changes, as well as alterations in human behavior. The anthrax vaccine is primarily employed to defend against anthrax and research is currently investigating its potential for wider use in warding off other infectious diseases through its immunogenic attributes and versatility. For example, the US-based nonprofit organization, the Council on Foreign Relations reported in February 2023 that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases originated from zoonotic sources. Additionally, across the globe, zoonoses result in 2.7 million human deaths and 2.5 billion instances of illness every year. Hence, the escalating occurrence of diseases is propelling the anthrax vaccine market’s growth.

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Which Emerging Trends And Strategic Shifts Are Shaping The Anthrax Vaccine Market?

Main players in the anthrax vaccine market are concentrated on generating innovative vaccines and acquiring FDA authentication. This certification confirms that the vaccine has undergone meticulous clinical trials and is deemed safe for public consumption, safeguarding individuals from potential harmful effects. For example, Emergent BioSolutions Inc., a biopharmaceutical firm based in the United States, received the green light for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly referred to as AV7909, from the U.S. Food and Drug Administration (FDA) in July 2023. The approval relied on data extracted from a Phase 2 trial that analyzed Cyfendus’s lack of interference with antibacterial medicines, and a Phase 3 clinical study that compared the immunogenicity and safety of the vaccine to BioThrax, its predecessor. Moreover, it is essential to create safer and more efficient adjuvants to tackle problems related to reactogenicity and optimize the overall efficacy of anthrax vaccines.

What Are The Most Active Companies In The Anthrax Vaccine Market Today?

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Which Regional Markets Are Attracting The Most Investment In Anthrax Vaccine?

North America was the largest region in the anthrax vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15511&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model